DSM and Firmenich have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. The Dutch specialty chemicals maker has said that this merge with Swiss
Tags :Walder Wyss
Zuger Kantonalbank is acquiring Immofonds Asset Management, which acts, among other things, as the fund management for IMMOFONDS. Zuger Kantonalbank wants to increase its share in the real estate sector. Earlier in the year, the
Demant has negotiated an agreement with the intention to divest its Hearing Implants business, Oticon Medical, to Cochlear Limited for a total consideration of DKK 850 million. The transaction follows a review of strategic options for
A private family office has acquired the whole outstanding share capital of Qcenter from SR Fund I. The fund was initiated and managed by Swissroc Investment and comprising a handful of local entrepreneurs. The private
The Collana IT Group has acquired Data Dynamic, a provider for business solutions located in Bern. The longstanding relationship with Microsoft and the expertise in Dynamics 365 Business Central is the basis for customized solutions in
Westhive, providers of flexible office space, successfully closes its Series A financing round raising CHF 6.3 million. The round is co-led by the Fairway Family Office and Redstone powered MA Ventures, the corporate venture capital fund
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Walder Wyss has announced the appointment of Ryan Houdrouge (pictured) as a partner. With his addition the firm strengthens the Geneva office and expands its services on administrative law as well as all areas of
Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from
